ArticleInfection and drug resistance2026
Successful Treatment of Carbapenem-Resistant
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sulbactam-Durlobactam (SUL-DUR), a novel β-lactam/β-lactamase inhibitor combination, exhibits potent activity against Methods: We describe two critically ill patients with severe CRAB infections who were successfully treated with SUL-DUR. Clinical characteristics, microbiological findings, antimicrobial regimens, treatment responses, and clinical outcomes were reviewed. The rationale for selecting combination therapy or monotherapy was described according to infection characteristics and individual clinical considerations. Results: The first patient developed CRAB bloodstream infection following severe trauma and was successfully treated with SUL-DUR combined with imipenem-cilastatin, achieving rapid clearance of blood cultures and clinical improvement. The second patient developed CRAB pneumonia in the context of pulmonary Conclusion: These two cases expand the clinical experience of SUL-DUR in severe CRAB infections, demonstrating successful treatment of CRAB bloodstream infection with SUL-DUR-based combination therapy and favorable outcomes of individualized SUL-DUR monotherapy for selected monomicrobial CRAB pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.